The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Abstract
Purpose: Protein kinase C beta (PKCβ) was identified by gene-expression profiling, preclinical evaluation, and independent immunohistochemical analysis as a rational therapeutic target in diffuse large B-cell lymphoma (DLBCL). We conducted a multicenter phase II study of a potent inhibitor of PKCβ, enzastaurin, in patients with relapsed or refractory DLBCL. Patients and Methods: Enzastaurin was taken orally once daily until disease progression or unacceptable toxicity occurred. Study end points included freedom from progression (FFP) for ≥ two cycles (one cycle = 28 days), objective response, and toxicity. Results: Fifty-five patients (median age, 68 years) were enrolled. Patients had received a median number of two prior therapies (range, one to five); six patients relapsed after high-dose therapy and autologous stem-cell transplantation. Only one grade 4 toxicity (hypomagnesemia) occurred. Grade 3 toxicities included fatigue (n = 2), edema (n = 1), headache (n = 1), motor neuropathy (n = 1), and thrombocytopenia (n = 1). No grade 3 or 4 neutropenia occurred. No deaths or discontinuations due to toxicity were reported. Fifteen patients completed less than one cycle of therapy. Twelve of 55 patients (22%; 95% CI, 13% to 46%) experienced FFP for ≥ two cycles, and eight patients remained free from progression for ≥ four cycles (15%; 95% CI, 6% to 27%). Four patients (7%; 95% CI, 2% to 18%), including three complete responders and one patient with stable disease, continue to experience FFP 20+ to 50+ months after study entry. Conclusion: Treatment with enzastaurin was well-tolerated and associated with prolonged FFP in a small subset of patients with relapsed or refractory DLBCL. Further studies of enzastaurin in DLBCL are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suzuma, K., Takahara, N., Suzuma, I., Isshiki, K., Ueki, K., Leitges, M., Aiello, L. P., & King, G. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022644499 · Cited by 170
Cited by
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Protein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563
Sehn, L. H., & Gascoyne, R. D. (2015) · Blood · doi:10.1182/blood-2014-05-577189 · Cited by 560
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Friedberg, J. W. (2011) · Hematology · doi:10.1182/asheducation-2011.1.498 · Cited by 497
Martelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 411
Targeting pathological B cell receptor signalling in lymphoid malignancies
Young, R. M., & Staudt, L. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3937 · Cited by 401
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.07.049 · Cited by 381
Friedberg, J. W., & Fisher, R. I. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.07.002 · Cited by 362
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.08.033 · Cited by 347
Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
Boyle, G. M., D'Souza, M. M. A., Pierce, C. J., Adams, R. A., Cantor, A. S., Johns, J. P., Maslovskaya, L., Gordon, V. A., Reddell, P. W., & Parsons, P. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108887 · Cited by 101
Equivocal, explicit and emergent actions of PKC isoforms in cancer
Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00310-4 · Cited by 65
Enzastaurin: A lesson in drug development
Bourhill, T., Narendran, A., & Johnston, R. N. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.003 · Cited by 55
Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma
Huynh, M. Q., Goßmann, J., Gattenlöehner, S., Klapper, W., Wacker, H.-H., Ramaswamy, A., Bittner, A., Kaiser, U., & Neubauer, A. (2015) · Leukemia & Lymphoma · doi:10.3109/10428194.2014.941832 · Cited by 8
Metadata
- Authors
- Robertson, M. J., Kahl, B. S., Vose, J. M., de Vos, S., Laughlin, M., Flynn, P. J., Rowland, K., Cruz, J. C., Goldberg, S. L., Musib, L., Darstein, C., Enas, N., Kutok, J. L., Aster, J. C., Neuberg, D., Savage, K. J., LaCasce, A., Thornton, D., Slapak, C. A., & Shipp, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-05-01
- Volume
- 25
- Issue
- 13
- Pages
- 1741-1746
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120601121
- Cited by
- 232
- References
- 1
- FWCI
- 16.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.